Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $12,694 | $4,208 | $9,384 | $32,562 |
| % Growth | 201.7% | -55.2% | -71.2% | – |
| Cost of Goods Sold | $8,182 | $5,233 | $1,718 | $998 |
| Gross Profit | $4,512 | -$1,025 | $7,666 | $31,564 |
| % Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| R&D Expenses | $48,311 | $37,041 | $28,084 | $35,698 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $79,551 | $67,619 | $56,226 | $27,469 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $544 |
| Operating Expenses | $127,862 | $104,660 | $84,310 | $63,167 |
| Operating Income | -$123,350 | -$105,685 | -$76,644 | -$31,603 |
| % Margin | -971.7% | -2,511.5% | -816.8% | -97.1% |
| Other Income/Exp. Net | $47,859 | $40,543 | -$17,817 | $22,269 |
| Pre-Tax Income | -$75,491 | -$65,142 | -$97,023 | -$9,334 |
| Tax Expense | -$51,751 | -$44,848 | $3,560 | -$21,725 |
| Net Income | -$23,740 | -$20,294 | -$100,583 | $12,391 |
| % Margin | -187% | -482.3% | -1,071.9% | 38.1% |
| EPS | -0.17 | -0.18 | -0.73 | 0.09 |
| % Growth | 5.6% | 75.3% | -912% | – |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| Weighted Avg Shares Out | 138,707 | 113,328 | 137,799 | 137,799 |
| Weighted Avg Shares Out Dil | 138,707 | 113,328 | 137,799 | 137,799 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1,415 |
| Interest Expense | $3,892 | $0 | $2,562 | $0 |
| Depreciation & Amortization | -$46,049 | -$46,740 | $1,429 | -$20,101 |
| EBITDA | -$169,399 | -$152,425 | -$75,215 | -$51,704 |
| % Margin | -1,334.5% | -3,622.3% | -801.5% | -158.8% |